PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.06 · Revenue $0.00 · 1 analysts
Est. EPS $-0.05 · Revenue $0.00 · 1 analysts
Est. EPS $-45.00 · Revenue $0.00 · 1 analysts
Est. EPS $-0.07 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-19.4M | -163.4% | -688.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-5.2M | -73.0% | -77.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | — | — |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 45.28x | +489.8% | +267.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $46.8M | -15.3% | -16.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.77 vs -45.00 | +93.8% | -0.46 vs -0.06 | -666.7% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | WALKER WAYNE REMELL | director | Stock Option (Right to Buy) | A | 0 | — |
| Mar 31, 2026 | Abecassis Michael M | director | Stock Option (Right to Buy) | A | 0 | — |
| Mar 31, 2026 | SCHECHTER JONATHAN | director | Stock Option (Right to Buy) | A | 0 | — |
| Mar 31, 2026 | WEINSTEIN ROBERT | director | Stock Option (Right to Buy) | A | 0 | — |
| Mar 31, 2026 | WEINSTEIN ROBERT | director | Stock Option (Right to Buy) | A | 119,170 | $0.67 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Joshua N. Silverman | Chief Executive Officer. President & Executive Chairman | USD 520,257 | Male | 1970 | Active |
Carlos A. Trujillo | Chief Financial Officer | USD 482,017 | Male | 1958 | Active |
Hans-Peter Hammes | Member of Medical & Scientific Advisory Board and Consultant | — | — | — | Active |
Jose L. Iglesias | Consulting Chief Medical Officer | — | — | 1957 | Active |
This article is a Form 4/A filing from PharmaCyte Biotech, detailing a statement of changes in beneficial ownership of securities for Director Michael M. Abecassis. The document itself would contain the specific transaction details.
This article is a 10-K Annual Report filing for PharmaCyte Biotech for the fiscal year 2026. The 10-K report contains comprehensive financial performance details for the company during the stated fiscal year.
This article provides current stock information for PharmaCyte Biotech Inc (PMCB), including its latest stock price, daily change, market cap, and links to financial data, analyst ratings, and news. As of the report, PMCB closed at $0.553 with a 1.37% increase, and indicated that more news about the company is expected soon. The platform "TradingKey" serves as the source for this investment data.
This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's current stock price, market capitalization, and various financial metrics. The article also lists peer comparisons and indicates that the financial forecasting data was updated on August 7, 2026.
This article provides a technical analysis of PharmaCyte Biotech Inc (PMCB), detailing its current price momentum score, support and resistance levels, and indicator and moving average assessments. It highlights that PMCB's stock price is currently trading between a resistance level of 0.71 and a support level of 0.49, suggesting suitability for range-bound swing trading. The analysis also summarizes various technical indicators and moving averages, with a current overall neutral signal.
